A new medicine does not walk into the world wearing a name tag. It begins as evidence: a collection of endpoints, confidence intervals, adverse events, and arguments about what the results mean. A scientist sees a mechanism. A clinician sees a possible change in practice. A payer sees a price arriving with paperwork. A patient sees, if everything goes well, another Tuesday.
Between those people sits a peculiar commercial problem. The same truth must be translated several times without being bent out of shape. The people who write a manuscript are not usually the people who negotiate reimbursement. The people who interview patients are not always the people who build a launch plan. Each handoff creates a chance to lose the plot.
Citrus Health Group is built around those handoffs. The Chicago consultancy works for pharmaceutical, biotech, diagnostic, and medical-device companies. It plans evidence, writes publications, prepares medical teams, develops value stories, studies payer behavior, designs patient-support programs, creates brands, and runs meetings. This is not drug manufacturing, despite the industry label that follows the company around online. Citrus manufactures coherence.
The company assembled backwards
Most companies start with one service and add neighboring capabilities over time. The current Citrus arrived in March 2023 already carrying history. Healthcare investor NaviMed Capital backed a combination built on Prescott Medical Communications and an earlier Citrus consultancy founded by John “Zeke” Czekanski and Scott Roberts. The new platform was led by Neil Matheson, a longtime medical-communications entrepreneur.
Then came the buying. In September 2023, Citrus acquired MedLogix Communications, founded in 2000, adding medical affairs, scientific content, and meeting operations. Three weeks later it acquired The Curry Rockefeller Group, another scientific-communications specialist with roots in 2001. In September 2024 it bought Mirador Global, whose work in forecasting, commercialization strategy, and launch planning moved Citrus earlier in a medicine's journey.
The acquisition prices were not disclosed. NaviMed's investment was not disclosed either, nor was the size of the unitranche debt supplied by Five Points Capital. The public result is easier to measure. An industry survey reported that North American revenue rose from $17.1 million in 2022 to $29.912 million in 2023. Full-time staff went from 63 to 146. Client count climbed from 26 to 64.
Roll-ups often look obvious from a distance. Buy adjacent firms. Combine the accounting. Cross-sell. Up close, they can resemble a dinner party where everyone brought a chef and nobody agreed on the menu. The specialist reputations are the reason to buy the firms; smoothing them into one anonymous network can destroy the thing purchased.
The revealing number is 84
Citrus describes itself as a “global consultancy” with “boutique strategic focus.” Those phrases usually tug in opposite directions. Global suggests breadth, systems, and coverage. Boutique suggests a principal who knows the work and a team that was chosen for this problem. Citrus tries to reconcile them with what it calls a time-of-need model: use the wider bench, but bring in a specialist only when the asset needs that expertise.
The best evidence that clients bought the idea is not the jump in client count. It is that 84 percent of reported 2023 growth came from existing clients. Only 16 percent came from new ones. In other words, the bigger platform found most of its extra business among people already paying somebody inside it.
That is cross-selling, certainly, but the phrase undersells what is happening. A drug developer rarely wakes up wanting “more agency.” It discovers that a clinical plan has left a payer question unanswered, or that a beautiful scientific narrative does not explain affordability, or that a launch dashboard is flashing red because nobody owns the dependency between evidence and access. Citrus can move a neighboring expert into the room without asking the client to begin another agency search.
The product is not a brochure, a publication, or a payer deck. It is a cleaner handoff.
Four doors into the same room
The unified company now presents four main practices. Citrus Scientific covers scientific strategy, publications, medical affairs, key-opinion-leader engagement, training, congress work, and omnichannel education. Citrus Commercialization & Access advises from portfolio prioritization and investment decisions through launch readiness, pricing, reimbursement, and evidence generation. Citrus Engage handles brand planning, payer communications, patient advocacy, affordability, adherence, and support programs. Citrus Connect runs advisory boards, investigator meetings, congress programs, and speaker bureaus.
The customers are life-sciences companies, from large pharmaceutical businesses to startups. The work matters most when the science is complicated, the treatment is expensive, the therapeutic field is crowded, or the route to reimbursement is uncertain. Citrus lists depth in oncology, rare disease, neurology and mental health, immunology, dermatology, metabolic disease, and cardiovascular medicine. Those are fields where a fuzzy value story becomes expensive quickly.
Map the customer's whole journey. Circle the costly handoffs. Add expertise around those breaks, centralize the invisible operations, and test the wider offer first with clients who already trust you. The sequence matters more than the service menu.
There are limits. A buyer who needs one narrow manuscript may prefer a smaller specialist. A pharmaceutical company may deliberately split work among agencies to manage conflicts or preserve independent advice. And a roll-up only earns the word “integrated” when people, incentives, and information actually cross the old company lines. Shared email addresses do not count.
The integration test is human
Citrus's stated values are quality, respect, agility, and excellence. More concrete signals sit underneath: flexible remote or Chicago work, a 12-month fellowship for postdoctoral scientists, a journal club, an AI task force, and twice-monthly Coffee Corner sessions. Its chief medical officer, Beth McMahon, brings more than 25 primary or senior-author publications and four patents. That mix of academic fluency and agency delivery is the labor model in miniature.
The company also inherited founders and leaders from the firms it acquired. MedLogix co-founder Susan Sessa became chief operating officer. Curry Rockefeller president Jeff Keller took responsibility for scientific communications. Mirador founder Chuck Peipher became chief strategy officer. This is sensible integration theater: the acquired expertise remains visible, and the people associated with it keep authority.
The harder work happens below the biographies. Can the evidence planner recognize a reimbursement problem early? Can the brand strategist hear when a patient-support promise exceeds the operating reality? Can a meeting team capture an insight and return it to strategy instead of filing it with the catering invoice? Citrus's market position rests on answering yes often enough that one client keeps opening the next door.
A molecule becomes a medicine through chemistry and trials. It becomes an understood, valued, reimbursed, and usable medicine through translation. Citrus has assembled a company for the second journey. Its wager is modest in wording and ambitious in practice: the fewer times a client has to explain the science again, the more likely everyone is still talking about the same thing when it reaches the patient.